Chimeric Therapeutics Limited (CHM) Fair Value & Analysis
Healthcare · AU · Market cap A$4.4M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from A$0.1600 to A$0.0703 (−56.0%) since Jun 24, 2026. Share price −35.0% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0630 – A$0.5908 · fair‑value band A$0.0456 – A$0.0991 · the A$0.0640 price screens below the A$0.0703 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Chimeric Therapeutics Limited (CHM) currently trades at A$0.0640, while our model-based Fair Value estimate is A$0.0703 — implying the stock looks roughly 9.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$9.7M. Revenue declined 52.8% year over year. The balance sheet holds a net cash position of A$5.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chimeric Therapeutics Limited reported revenue of A$4.0M in FY2025 versus A$2.6K in FY2021, a compound +522.3%/yr. Reported net income was −A$10.4M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chimeric Therapeutics Limited (CHM) undervalued?
What is the fair value of CHM?
What is the quality score of CHM?
What is the revenue of Chimeric Therapeutics Limited (CHM)?
What is the net profit margin of CHM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.